Company registration number 07224430 (England and Wales)
Ian Simmons Ophthalmics Limited
Unaudited Financial Statements
For The Year Ended 29 September 2025
Pages For Filing With Registrar
IAN SIMMONS OPHTHALMICS LIMITED
Ian Simmons Ophthalmics Limited
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 9
IAN SIMMONS OPHTHALMICS LIMITED
Ian Simmons Ophthalmics Limited
BALANCE SHEET
AS AT
29 SEPTEMBER 2025
29 September 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
8,282
11,452
Investments
5
939,664
420,829
947,946
432,281
Current assets
Debtors
6
608,619
722,393
Cash at bank and in hand
500,755
489,569
1,109,374
1,211,962
Creditors: amounts falling due within one year
7
(280,096)
(310,860)
Net current assets
829,278
901,102
Total assets less current liabilities
1,777,224
1,333,383
Provisions for liabilities
(2,000)
(2,863)
Net assets
1,775,224
1,330,520
Capital and reserves
Called up share capital
240
240
Profit and loss reserves
1,774,984
1,330,280
Total equity
1,775,224
1,330,520
IAN SIMMONS OPHTHALMICS LIMITED
Ian Simmons Ophthalmics Limited
BALANCE SHEET (CONTINUED)
AS AT
29 SEPTEMBER 2025
29 September 2025
- 2 -

For the financial year ended 29 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements. true

The financial statements were approved by the board of directors and authorised for issue on 13 May 2026 and are signed on its behalf by:
Mr I G Simmons
Director
Company registration number 07224430 (England and Wales)
IAN SIMMONS OPHTHALMICS LIMITED
Ian Simmons Ophthalmics Limited
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 29 SEPTEMBER 2025
- 3 -
1
Accounting policies
Company information

Ian Simmons Ophthalmics Limited is a private company limited by shares incorporated in England and Wales. The registered office is C/O Azets, 12 King Street, Leeds, LS1 2HL.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2
Going concern

A true t the time of approving the financial statements, t he directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes.

1.4
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% reducing balance basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

IAN SIMMONS OPHTHALMICS LIMITED
Ian Simmons Ophthalmics Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 29 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 4 -
1.6
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.7
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

IAN SIMMONS OPHTHALMICS LIMITED
Ian Simmons Ophthalmics Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 29 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

IAN SIMMONS OPHTHALMICS LIMITED
Ian Simmons Ophthalmics Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 29 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 6 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

IAN SIMMONS OPHTHALMICS LIMITED
Ian Simmons Ophthalmics Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 29 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 7 -
1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
2
2
3
Intangible fixed assets
Goodwill
£
Cost
At 30 September 2024 and 29 September 2025
120,000
Amortisation and impairment
At 30 September 2024 and 29 September 2025
120,000
Carrying amount
At 29 September 2025
-
0
At 29 September 2024
-
0
IAN SIMMONS OPHTHALMICS LIMITED
Ian Simmons Ophthalmics Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 29 SEPTEMBER 2025
- 8 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 30 September 2024
27,224
Disposals
(3,671)
At 29 September 2025
23,553
Depreciation and impairment
At 30 September 2024
15,772
Depreciation charged in the year
2,862
Eliminated in respect of disposals
(3,363)
At 29 September 2025
15,271
Carrying amount
At 29 September 2025
8,282
At 29 September 2024
11,452
5
Fixed asset investments
2025
2024
£
£
Other investments other than loans
939,664
420,829
Movements in fixed asset investments
Investments
£
Cost or valuation
At 30 September 2024
420,829
Additions
497,500
Valuation changes
23,868
At 29 September 2025
942,197
Impairment
At 30 September 2024
-
Impairment losses
2,533
At 29 September 2025
2,533
Carrying amount
At 29 September 2025
939,664
At 29 September 2024
420,829
IAN SIMMONS OPHTHALMICS LIMITED
Ian Simmons Ophthalmics Limited
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 29 SEPTEMBER 2025
- 9 -
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
354,339
495,233
Other debtors
254,280
227,160
608,619
722,393
7
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
1,124
710
Taxation and social security
270,032
300,760
Other creditors
8,940
9,390
280,096
310,860
8
Directors' transactions

At the year end, the balance of the loan owed to the company by the directors was £252,817 (2024 - £225,499). During the year there were advances of £283,433 (2024 - £317,245) and repayments of £262,507 (2024 - £262,423). Interest was charged at 2.25% per annum being £6,392 (2024 - £2,927).

Dividends totalling £250,000 (2024 - £250,000) were paid in the year in respect of shares held by the company's directors.

2025-09-29 2024-09-30 false false false 13 May 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr I G Simmons Mrs A J Simmons 07224430 2024-09-30 2025-09-29 07224430 2025-09-29 07224430 2024-09-29 07224430 core:OtherPropertyPlantEquipment 2025-09-29 07224430 core:OtherPropertyPlantEquipment 2024-09-29 07224430 core:CurrentFinancialInstruments core:WithinOneYear 2025-09-29 07224430 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-29 07224430 core:WithinOneYear 2025-09-29 07224430 core:WithinOneYear 2024-09-29 07224430 core:CurrentFinancialInstruments 2025-09-29 07224430 core:CurrentFinancialInstruments 2024-09-29 07224430 core:ShareCapital 2025-09-29 07224430 core:ShareCapital 2024-09-29 07224430 core:RetainedEarningsAccumulatedLosses 2025-09-29 07224430 core:RetainedEarningsAccumulatedLosses 2024-09-29 07224430 bus:Director1 2024-09-30 2025-09-29 07224430 core:Goodwill 2024-09-30 2025-09-29 07224430 core:FurnitureFittings 2024-09-30 2025-09-29 07224430 2023-09-30 2024-09-29 07224430 core:NetGoodwill 2024-09-29 07224430 core:NetGoodwill 2025-09-29 07224430 core:NetGoodwill 2024-09-29 07224430 core:OtherPropertyPlantEquipment 2024-09-29 07224430 core:OtherPropertyPlantEquipment 2024-09-30 2025-09-29 07224430 bus:PrivateLimitedCompanyLtd 2024-09-30 2025-09-29 07224430 bus:SmallCompaniesRegimeForAccounts 2024-09-30 2025-09-29 07224430 bus:FRS102 2024-09-30 2025-09-29 07224430 bus:AuditExemptWithAccountantsReport 2024-09-30 2025-09-29 07224430 bus:Director2 2024-09-30 2025-09-29 07224430 bus:FullAccounts 2024-09-30 2025-09-29 xbrli:pure xbrli:shares iso4217:GBP